Christine M. Lovly, MD, PhD

Christine Lovly, MD, PhD, shares data on BDTX-1535, a “masterkey” EGFR inhibitor targeting classical, non-classical, and the C797S resistance mutation in patients with EGFR mutant non-small cell lung cancer (NSCLC), from a presentation at AACR 2024.

Christine M. Lovly, MD, PhD, discusses the investigation of the EGFR inhibitor BDTX-1535 in patients with non–small cell lung cancer.